GM2 Gangliosidosis (Tay-Sachs Disease), type I, Infantile Form: Clinical Case
https://doi.org/10.15690/vsp.v23i4.2770
Abstract
Background. GM2 gangliosidosis (Tay-Sachs disease, variant B, type I) is an orphan disease with autosomal recessive inheritance. It develops due to gangliosides accumulation in tissues and organs. The description of clinical case of GM2 gangliosidosis in the patient originating from the Buryat nationality has been presented for the first time. Clinical case description. Girl, 1 year 4 months old, parents — Buryats. There were the following complaints at their admission to the neurology department: lack of movement in the limbs, the child has stopped turning over, became lethargic, slowly ate supplemental feeding. Biochemical blood test has shown increased aspartate aminotransferase activity by 6 times from normal upper limit. α-galactosidase, α-glucosidase, β-D-glucosidase, sphingomyelinase, galactocerebrosidase, and α-iduronidase activities were within the reference levels. Sanger sequencing has revealed the nucleotide variant chr15:72346680G>A (GRCh38) in homozygous state in the HEXA gene. The diagnosis has been established: “GM2 gangliosidosis, type I, infantile form”. Conclusion. GM2 gangliosidosis is a rare disease, especially among Asian populations. Moreover, GM2 gangliosidosis is inherited in autosomal recessive way, thus, two children in the described family had the disease (the first child was assumed to have the disease according to the clinical signs)
About the Authors
Artem A. Babkin
Chita State Medical Academy
Russian Federation
Disclosure of interest:
Russian Federation
Chita
Disclosure of interest:
Not declared
Vladimir A. Shcherbak
Chita State Medical Academy
Russian Federation
Disclosure of interest:
Russian Federation
Chita
Disclosure of interest:
Not declared
Elena V. Leontieva
Krai Children’s Clinical
Russian Federation
Disclosure of interest:
Russian Federation
Chita
Disclosure of interest:
Not declared
Lada A. Kirii
Krai Children’s Clinical
Russian Federation
Disclosure of interest:
Russian Federation
Chita
Disclosure of interest:
Not declared
References
1. Solovyeva VV, Shaimardanova AA, Chulpanova DS, et al. TaySachs disease: diagnostic, modeling and treatment approaches. Genes & Cells. 2020;15(1):17–22. (In Russ). doi: https://doi.org/10.23868/202003002
2. Liu Z, Zhao R. Generation of HEXA-deficient hiPSCs from fibroblasts of a Tay-Sachs disease patient. Stem Cell Res. 2016;17(2):289–291. doi: https://doi.org/10.1016/j.scr.2016.08.010
3. Rozenberg R, Pereira L da V. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program. Sao Paulo Med J. 2001;119(4):146–149. doi: https://doi.org/10.1590/s1516-31802001000400007
4. Gravel R, Kaback MM, Proia RL, et al. The GM2 gangliosidoses. In: Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, eds. 8th edn. New York, NY, USA: McGraw-Hill; 2001. pp. 3827–3876.
5. Gowda VK, Gupta P, Bharathi NK, et al. Clinical and Laboratory Profile of Gangliosidosis from Southern Part of India. J Pediatr Genet. 2020;11(1):34–41. doi: https://doi.org/10.1055/s-0040-1718726
6. Karimzadeh P, Jafari N, Nejad Biglari H, et al. GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series). Iran J Child Neurol. 2014;8(3):55–60.
7. İnci A, Cengiz Ergin FB, Biberoğlu G, et al. Two patients from Turkey with a novel variant in the GM2A gene and review of the literature. J Pediatr Endocrinol Metab. 2021;34(6):805–812. doi: https://doi.org/10.1515/jpem-2020-0655
8. Kaback MM, Desnick RJ. Hexosaminidase A Deficiency. In: GeneReviews® [Internet]. Pagon RA, Adam MP, Bird TD, et al., eds. Seattle (WA): University of Washington, Seattle; 2011. Available online: https://web.archive.org/web/20140116030612/http://www.ncbi.nlm.nih.gov/books/NBK1218. Accessed on April 01, 2024.
9. Leal AF, Benincore-Flórez E, Solano-Galarza D, et al. GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies. Int J Mol Sci. 2020;21(17):6213. doi: https://doi.org/10.3390/ijms21176213
10. Park JH, Ko JM, Kim MS, et al. Novel HEXA variants in Korean children with Tay-Sachs disease with regression of neurodevelopment from infancy. Mol Genet Genomic Med. 2021;9(6):e1677. doi: https://doi.org/10.1002/mgg3.1677
11. Ferreira CR, Gahl WA. Lysosomal storage diseases. Transl Sci Rare Dis. 2017;2(1-2):1–71. doi: https://doi.org/10.3233/TRD-160005
Review
For citations:
Babkin A.A., Shcherbak V.A., Leontieva E.V., Kirii L.A. GM2 Gangliosidosis (Tay-Sachs Disease), type I, Infantile Form: Clinical Case. Current Pediatrics. 2024;23(4):247-251. (In Russ.) https://doi.org/10.15690/vsp.v23i4.2770
Views:
300
Email this article 
